[1] Brindley P J, Bachini M, Ilyas S I, et al, et al. Cholangiocarcinoma[J]. Nat Rev Dis Primers, 2021, 7(1):65.
[2] Rodrigues P M, Banales J M. RePARylating biliary tumours to improve the efficacy of chemoimmunotherapy[J]. J Hepatol, 2026, 84(3):496-498.
[3] Ilyas S I, Affo S, Goyal L, et al. Cholangiocarcinoma-novel biological insights and therapeutic strategies[J]. Nat Rev Clin Oncol, 2023, 20(7):470-486.
[4] Forner A, Vidili G, Rengo M, et al. Clinical presentation, diagnosis and staging of cholangiocarcinoma[J]. Liver Int, 2019, 39 Suppl 1:98-107.
[5] Bernstein C N, Benchimol E I, Bitton A, et al. The impact of inflammatory bowel disease in Canada 2018: extra-intestinal diseases in IBD[J]. J Can Assoc Gastroenterol, 2019, 2(Suppl 1):S73-S80.
[6] Wang W, Smits R, Hao H, et al. Wnt/β-Catenin signaling in liver cancers[J]. Cancers (Basel), 2019, 11(7):926.
[7] Yu T H, Chen X, Zhang X H, et al. Clinicopathological characteristics and prognostic factors for intrahepatic cholangiocarcinoma: a population-based study[J]. Sci Rep, 2021, 11(1):3990.
[8] Raggi C, Fiaccadori K, Pastore M, et al. Antitumor activity of a novel fibroblast growth factor receptor inhibitor for intrahepatic cholangiocarcinoma[J]. Am J Pathol, 2019, 189(10):2090-2101.
[9] Zhu A X, Macarulla T, Javle M M, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial[J]. JAMA Oncol, 2021, 7(11):1669-1677.
[10] Czauderna C, Kirstein M M, Tews H C, et al. Molecular subtypes and precision oncology in intrahepatic cholangiocarcinoma[J]. J Clin Med, 2021, 10(13):2803.
[11] Dong Z, Liao B, Shen W, et al. Expression of programmed death ligand 1 is associated with the prognosis of intrahepatic cholangiocarcinoma[J]. Dig Dis Sci, 2020, 65(2):480-488.
[12] Martín-Sierra C, Martins R, Laranjeira P, et al. Functional and phenotypic characterization of tumor-infiltrating leukocyte subsets and their contribution to the pathogenesis of hepatocellular carcinoma and cholangiocarcinoma[J]. Transl Oncol, 2019, 12(11):1468-1479.
[13] Zhang Y, Luo J, Dong X, et al. Establishment and characterization of two novel cholangiocarcinoma cell lines[J]. Ann Surg Oncol, 2019, 26(12):4134-4147.
[14] Illuzzi G, Fouquerel E, Amé J C, et al. PARG is dispensable for recovery from transient replicative stress but required to prevent detrimental accumulation of poly(ADP-ribose) upon prolonged replicative stress[J]. Nucleic Acids Res, 2014, 42(12):7776-7792.
[15] Yu M, Chen Z, Zhou Q, et al. PARG inhibition limits HCC progression and potentiates the efficacy of immune checkpoint therapy[J]. J Hepatol, 2022, 77(1):140-151.
[16] Slade D, Dunstan M S, Barkauskaite E, et al. The structure and catalytic mechanism of a poly(ADP-ribose) glycohydrolase[J]. Nature, 2011, 477(7366):1616-1620.
[17] Shirai H, Poetsch A R, Gunji A, et al. PARG dysfunction enhances DNA double strand break formation in S-phase after alkylation DNA damage and augments different cell death pathways[J]. Cell Death Dis, 2013, 4(6):e656.
[18] Houl J H, Ye Z, Brosey C A, et al. Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death[J]. Nat Commun, 2019, 10(1):5654.
[19] Kaufmann T, Grishkovskaya I, Polyansky A A, et al. A novel non-canonical PIP-box mediates PARG interaction with PCNA[J]. Nucleic Acids Res, 2017, 45(16):9741-9759.
[20] Vekariya U, Minakhin L, Chandramouly G, et al. PARG is essential for Polθ-mediated DNA end-joining by removing repressive poly-ADP-ribose marks[J]. Nat Commun, 2024, 15(1):5822.
[21] Yu M, Xie P, Yu Q, et al. PARG inhibition halts cholangiocarcinoma progression via the Hippo pathway and enhances response to chemotherapy and immunotherapy[J]. Journal of Hepatology, 2026, 84(3):599-617.
[22] Martincuks A, Zhang C, Austria T, et al. Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer[J]. J Immunother Cancer, 2024, 12(4).
[23] Hwang S, Woo S, Kang B, et al. Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer[J]. J Hepatol, 2025, 82(4):649-657.
[24] Wen N, Peng D, Xiong X, et al. Cholangiocarcinoma combined with biliary obstruction: an exosomal circRNA signature for diagnosis and early recurrence monitoring[J]. Signal Transduct Target Ther, 2024, 9(1):107.
[25] Ravindranathan R, Somuncu O, da Costa A A B, et al. PARG inhibitor sensitivity correlates with accumulation of single-stranded DNA gaps in preclinical models of ovarian cancer[J]. Proc Natl Acad Sci U S A, 2024, 121(47):e2413954121.
[26] Jain A, Agostini L C, McCarthy G A, et al. Poly (ADP) ribose glycohydrolase can be effectively targeted in pancreatic cancer[J]. Cancer Res, 2019, 79(17):4491-4502.
[27] Min W, Cortes U, Herceg Z, et al. Deletion of the nuclear isoform of poly(ADP-ribose) glycohydrolase (PARG) reveals its function in DNA repair, genomic stability and tumorigenesis[J]. Carcinogenesis, 2010, 31(12):2058-2065.
[28] Acharya G, Mani C, Sah N, et al. CHK1 inhibitor induced PARylation by targeting PARG causes excessive replication and metabolic stress and overcomes chemoresistance in ovarian cancer[J]. Cell Death Discov, 2024, 10(1):278.
[29] Zhou Z, Qin P, Cheng X, et al. ChatGPT in oncology diagnosis and treatment: applications, legal and ethical challenges[J]. Curr Oncol Rep, 2025,27:336-354.
[30] Luo X, Cai T, Wu J, et al. Cost-effectiveness of pembrolizumab plus chemotherapy vs. chemotherapy as first-line treatment for advanced biliary tract cancer in China and the US[J]. Front Pharmacol, 2024, 15:1393559.
[31] Zhou Z, Zhou G, Zhou C, et al. Discovery of a potent, cooperative, and selective SOS1 PROTAC ZZ151 with in vivo antitumor efficacy in KRAS-mutant cancers[J]. J Med Chem, 2023, 66(6):4197-4214.
[32] Besselink M. The value of international collaboration in pancreatic cancer research: EURECCA[J]. Ann Surg Oncol, 2019, 26(3):705-706. |
